Choď na obsah Choď na menu
 


CV Bohac

updated 30.4.2019

CV concerning medicinal chemistry

(1987) he obtained RNDr. degree at Comenius University, Slovakia (expertise in organic and bioorganic chemistry)
(1993) PhD. Comenius University in Bratislava Faculty of Natural Sciences (organic and bioorganic chemistry)
(1993 – 1996) Postdoctoral fellowship under prof. Camille Ganter together with prof. Dieter Seebach at the Federal Institute of Technology (ETH) Zürich, Switzerland
(1987 – 2002) Assistant Professor at the Department of Organic Chemistry, Faculty of Natural Sciences, Comenius University in Bratislava, Slovakia
(since 2003) Associate Professor in Organic chemistry, Faculty of Natural Sciences, Comenius University in Bratislava with habilitation lecture from medicinal chemistry: Inhibition of Angiogenesis and Its Consequences in Cancer Treatment
(since 1991) supervised 37 graduated and 8 PhD students (other 1 PhD are ongoing)
(since 2003) introduced lectures and seminars from Medicinal Chemistry
(since 2010) composed and leads a research SME Biomagi, Ltd. (PIC number: 936 254 477) https://mch.estranky.sk/clanky/biomagi.html
(since 2010) Chair of Medicinal Chemistry Division of Slovak Chemical Society
in 2010 he obtained a prize: Pfizer Research Award for medicinal chemistry research results
(since 2011) Coordinator for Comenius University in Paul Ehrlich European PhD Network in Medicinal Chemistry http://www.pehrlichmedchem.eu/
Research in medicinal chemistry dedicated to inhibition of angiogenesis, targeting drug resistance in cancer stem cells, development of novel anti-neoplastic organic compounds by structure based drug design and Click chemistry methodology.
Author of 43 papers and 4 patents (Tramal, Allegra, …) , principal investigator or MC member of 12 research or international projects VEGA(6), APVV(3), COST(3)
He is employed at Comenius University in Bratislava, Slovakia (as a university teacher and researcher) and at SME Biomagi, Ltd (as CEO) where the research is focused on investigation of kinase conformations, ligand / target interaction analyses and development (computer predictions / organic synthesis / bioactivity evaluation / optimization of potential oncology therapeutics for VEGFR2, CLK, AXL, MER kinases, HDAC2 and SMO GPCR modulators (a part of the Hedgehog pathway in stem cells biology for anticancer or regenerative drugs). He identified an unknown conformation of tyrosine kinases possessing special intermediate DFG-(in/out) arrangement. His group has developed an effective prediction methodology to select target modulators from up to 8 millions of commercially available compounds.
 

--------------Malaga

(PI) principal investigator

(PI) (2018-2021) VEGA 1/0670/18 (The Research Grant Agency - Slovakia) Medicinal chemistry - effective development of inhibitors of selected key biological targets associated with tumor progression

(Member) (2016-2019) COST CA15135 Multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig)

(PI) (2016-2017) APVV-SK-FR-2015-0014 (The Slovak Research and Development Agency) Development of organic SMO and tyrosine kinase modulators as drug candidates

(PI) (2013-2016) VEGA 1/0634/13 (The Research Grant Agency - Slovakia) Synthesis and biological screening of computer-designed VEGFR-2 kinase inhibitors, application of knowledge for the development of inhibitors affecting cancer stem cell resistance

(MC member) (2012-2016) of COST Actions: CM1106 Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells (StemChem)

(Sub-coordinator) (2007-2011) COST Actions: CM0602: Inhibitors of angiogenesis: design, synthesis and biological exploitation (ANGIOKEM)

2019 Gen Physiol Biophys 38 157-163 J. Horváthová, R. Moravčík, A. Boháč, M. Zeman (DOI: 10.4149/gpb_2018047) Synergic effects of inhibition of glycolysis and multikinase receptor signalling on proliferation and migration of endothelial cells

2019 Chem Papers 73 71-84 J. Dobiaš, M. Ondruš, M. Hlaváč, M. Murár, J. Kóňa, G. Addová, A. Boháč (DOI: 10.1007/s11696-018-0576-6) Medicinal Chemistry - an effect of a desolvation penalty of an amide group in development of kinase inhibitors

2018 Chem Papers 72 2979-2985 (DOI: 10.1007/s11696-018-0548-x) M. Murár, J. Horvathová, R. Moravčík, G. Addová, M. Zeman, A. Boháč, Synthesis of glycolysis inhibitor (E)-3-(pyridin-3-yl)-1-(pyridin-4-yl)prop-2-en-1-one (3PO) and its inhibition of HUVEC proliferation alone or in a combination with the multi-kinase inhibitor sunitinib

2017 Eur J Med Chem 126, 754–761 (DOI: 10.1016/j.ejmech.2016.11.003) M. Murár, J. Dobiaš, P. Šramel, G. Addová, G. Hanquet, A. Boháč; Novel CLK1 Inhibitors Based on N-aryloxazol-2-amine Skeleton - a Possible Way to Dual VEGFR2 TK / CLK Ligands

2017 RCS MedChemComm 8, 81-87 (DOI: 10.1039/c6md00392c) Deniz Cansen Kahraman, Gilles Hanquet, Loïc Jeanmart, Steve Lanners, Peter Šramel, Andrej Boháč, Rengul Cetin-Atalay; Quinoides and VEGFR2 TKIs influence the fate of hepatocellular carcinoma and its cancer stem cells.

all PhD students were under supervision of A. Boháč, all students defended at Comenius University in Bratislava, Slovakia

Mgr. Matúš Hlaváč (2016- expected 2020) A rational development of inhibitors to influence tumour and diabetic diseases

Mgr. Miroslav Murár, Phd. (2014-2018) A rational development of tyrosine kinase and SMO inhibitors

Mgr. Juraj Dobiaš, Phd. (2013-2017) A rationale development of molecular drug candidates focused on cancer diseases

Mgr. Peter Šramel, Phd. (2013-2017) A synthesis and biological screening of predicted inhibitors of tyrosine kinases e.g. KDR

Mgr. Margaréta Vojtičková, Phd. (2008-2013) A development of VEGFR2 inhibitors by ynamides and Click chemistry approach

Mgr. Lucia Lintnerová, Phd. (2009-2013) Proposal of structures, synthesis and biological screening of VEGFR-2 tumour neovascularisation inhibitors

 

(1987) he obtained RNDr. degree at Comenius University, Slovakia (expertise in organic and bioorganic chemistry)
(1993) PhD. Comenius University in Bratislava, Faculty of Natural Sciences (organic and bioorganic chemistry)
(1993 – 1996) Postdoctoral fellowship under prof. Camille Ganter together with prof. Dieter Seebach at the Federal Institute of Technology (ETH) Zürich, Switzerland
(1987 – 2002) Assistant Professor at the Department of Organic Chemistry, Faculty of Natural Sciences, Comenius University in Bratislava, Slovakia
(since 2003) Associate Professor in Organic chemistry, Faculty of Natural Sciences, Comenius University in Bratislava with habilitation lecture from medicinal chemistry: Inhibition of Angiogenesis and Its Consequences in Cancer Treatment
(since 1991) supervised 37 graduated and 8 PhD students (other 1 PhD are ongoing)
(since 2003) introduced lectures and seminars from Medicinal Chemistry
(since 2010) composed and leads a research SME Biomagi, Ltd. (PIC number: 936 254 477) https://mch.estranky.sk/clanky/biomagi.html
(since 2010) Chair of Medicinal Chemistry Division of Slovak Chemical Society
in 2010 he obtained a prize: Pfizer Research Award for medicinal chemistry research results
(since 2011) Coordinator for Comenius University in Paul Ehrlich European PhD Network in Medicinal Chemistry http://www.pehrlichmedchem.eu/
Research in medicinal chemistry dedicated to inhibition of angiogenesis, targeting drug resistance in cancer stem cells, development of novel anti-neoplastic organic compounds by structure based drug design and Click chemistry methodology.
Author of 43 papers and 4 patents (Tramal, Allegra, …) , principal investigator or MC member of 12 research or international projects VEGA(6), APVV(3), COST(3)
He is employed at Comenius University in Bratislava, Slovakia (as a university teacher and researcher) and at SME Biomagi, Ltd (as CEO) where the research is focused on investigation of kinase conformations, ligand / target interaction analyses and development (computer predictions / organic synthesis / bioactivity evaluation / optimization of potential oncology therapeutics for VEGFR2, CLK, AXL, MER kinases, HDAC2 and SMO GPCR modulators (a part of the Hedgehog pathway in stem cells biology for anticancer or regenerative drugs). He identified an unknown conformation of tyrosine kinases possessing special intermediate DFG-(in/out) arrangement. His group has developed an effective prediction methodology to select target modulators from up to 8 millions of commercially available compounds.

 

 

 

Thesis direction (9)

Mgr. Matúš Hlaváč (2016- expected 2020) A rational development of inhibitors to influence tumour and diabetic diseases
Mgr. Miroslav Murár, Phd. (2014-2018) A rational development of tyrosine kinase and SMO inhibitors
Mgr. Juraj Dobiaš, Phd. (2013-2017) A rationale development of molecular drug candidates focused on cancer diseases
Mgr. Peter Šramel, Phd. (2013-2017) A synthesis and biological screening of predicted inhibitors of tyrosine kinases e.g. KDR
Mgr. Margaréta Vojtičková, Phd. (2008-2013) A development of VEGFR2 inhibitors by ynamides and Click chemistry approach
Mgr. Lucia Lintnerová, Phd. (2009-2013) Proposal of structures, synthesis and biological screening of VEGFR-2 tumour neovascularisation inhibitors
Mgr. Lucia Kušnierová, Phd. - Kováčiková (2008-2010) Proposal of leading structures, synthesis of organic angio- cancero-statics and their biological activity determination
Mgr. Ambróz Almassy, Phd.
Mgr. Branislav Horváth, Phd.

Research projects ()

(PI) principal investigator

(PI) (2018-2021) VEGA 1/0670/18 (The Research Grant Agency - Slovakia) Medicinal chemistry - effective development of inhibitors of selected key biological targets associated with tumor progression
(Member) (2016-2019) COST CA15135 Multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig)
(PI) (2016-2017) APVV-SK-FR-2015-0014 (The Slovak Research and Development Agency) Development of organic SMO and tyrosine kinase modulators as drug candidates
(PI) (2013-2016) VEGA 1/0634/13 (The Research Grant Agency - Slovakia) Synthesis and biological screening of computer-designed VEGFR-2 kinase inhibitors, application of knowledge for the development of inhibitors affecting cancer stem cell resistance
(MC member) (2012-2016) of COST Actions: CM1106 Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells (StemChem)
(Sub-coordinator) (2007-2011) COST Actions: CM0602: Inhibitors of angiogenesis: design, synthesis and biological exploitation (ANGIOKEM)
(PI) (2006-2009) LPP APVV 0153/06 (The Slovak Research and Development Agency) Design of leading structures, synthesis of organic angio- and cancerostatics, determination of their biological activity
(PI) (2005-2007) APVT-20-031904 (The Slovak Research and Development Agency)  Design of Structures and Synthesis of Active Low Molecular Angio- and Cancerostatics, Determination of Their Biological Activity, Development of New Therapeutics

Patents (4)

Lacova, M.; Bohac, A.; Biologically active compounds with pyrano[3,2-c]chromen-2(5H)-one skeleton and a method of their preparation Slovakia (2011), SK 287542 B6 20110104.
Bohac, A.; Snuparek, V.; Varga, I.; Gattnar, O.; Skoda, A.; Manduch, M. Method of production of trans-tramadol and its salts by epimerization of cis-tramadol Slovakia (2004), SK 284181 B6 20041005.
Veverka, M.; Boháč, A.; Almássy, A.; Addová, G.; Varga, I.; Method of preparation of derivatives of substituted 2-arylalkanoic acids by rearrangement of alpha-haloacetophenones and analogs in the presence of orthoformates and acid catalysts Patent No. WO 2004/046080 A1 – Geneva, World Intellectual Property Organization, 2004.
Veverka, M.; Boháč, A.; Križ, M.; Varga, I.; Method of preparation of terfenadine and its derivatives, Patent No. WO2004/043922 A1. Geneva, World Intellectual Property Organization, 2004.

Publications ()

2019 Gen Physiol Biophys 38 157-163 J. Horváthová, R. Moravčík, A. Boháč, M. Zeman (DOI: 10.4149/gpb_2018047) Synergic effects of inhibition of glycolysis and multikinase receptor signalling on proliferation and migration of endothelial cells
2019 Chem Papers 73 71-84 J. Dobiaš, M. Ondruš, M. Hlaváč, M. Murár, J. Kóňa, G. Addová, A. Boháč (DOI: 10.1007/s11696-018-0576-6) Medicinal Chemistry - an effect of a desolvation penalty of an amide group in development of kinase inhibitors
2018 Chem Papers 72 2979-2985 (DOI: 10.1007/s11696-018-0548-x) M. Murár, J. Horvathová, R. Moravčík, G. Addová, M. Zeman, A. Boháč, Synthesis of glycolysis inhibitor (E)-3-(pyridin-3-yl)-1-(pyridin-4-yl)prop-2-en-1-one (3PO) and its inhibition of HUVEC proliferation alone or in a combination with the multi-kinase inhibitor sunitinib
2017 Eur J Med Chem 126, 754–761 (DOI: 10.1016/j.ejmech.2016.11.003) M. Murár, J. Dobiaš, P. Šramel, G. Addová, G. Hanquet, A. Boháč; Novel CLK1 Inhibitors Based on N-aryloxazol-2-amine Skeleton - a Possible Way to Dual VEGFR2 TK / CLK Ligands
2017 RCS MedChemComm 8, 81-87 (DOI: 10.1039/c6md00392c) Deniz Cansen Kahraman, Gilles Hanquet, Loïc Jeanmart, Steve Lanners, Peter Šramel, Andrej Boháč, Rengul Cetin-Atalay; Quinoides and VEGFR2 TKIs influence the fate of hepatocellular carcinoma and its cancer stem cells.

etc.

2017 EJMECH 126, 754–761. link to the paper in EJMECH + PDF + suppl mat + videa DOI: 10.1016/j.ejmech.2016.11.003) M. Murár, J. Dobiaš, P. Šramel, G. Addová, G. Hanquet, A. Boháč; Novel CLK1 Inhibitors Based on N-aryloxazol-2-amine Skeleton - a Possible Way to Dual VEGFR2 TK / CLK Ligands

S.G. Kimani, S. Kumar, V. Davra, Y.-J. Chang, C. Kasikara, K. Geng, W.-I Tsou, S. Wang, M. Hoque, A. Boháč, A. Lewis-Antes, M.S. De Lorenzo, S.V. Kotenko, R.B. Birge Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase 2016 Cell Communication and Signaling, 14, DOI: 10.1186/s12964-016-0142-1. PDF,  The Journal

2017 RCS MedChemComm 8, 81-87 (DOI: 10.1039/c6md00392c, pdf + supplementary info) Deniz Cansen Kahraman, Gilles Hanquet, Loïc Jeanmart, Steve Lanners, Peter Šramel, Andrej Boháč, Rengul Cetin-Atalay; Quinoides and VEGFR2 TKIs influence the fate of hepatocellular carcinoma and its cancer stem cells.
2016 Gen Physiol Biophys 35 511-514, doi: 10.4149/gpb_2015055. 
R. Moravčík, K. Stebelová, A. Boháč, M. Zeman, Inhibition of VEGF mediated post receptor signalling pathways by recently developed tyrosine kinase inhibitor in comparison with sunitinib, pdf

--------------------------------------
upravit co si nizsie

 

M. Vojtičková, J. Dobiaš, G. Hanquet, G. Addová, R. Cetin-Atalay, D.C. Yildirim, A. Boháč, Ynamide Click chemistry in development of triazole VEGFR2 TK modulators, 2015 Eur. J. Med. Chem. 103 105-122,
DOI: 10.1016/j.ejmech.2015.08.012

2015 J Het Chem 52 425-39, DOI: 10.1002/jhet.2063
Lucia Lintnerová, Lucia Kováčiková, Gilles Hanquet, Andrej Boháč
Selected Methodologies Convenient for the Synthesis of N,5-Diaryloxazole-2-amine Pharmacophore.

2014 Eur J Med Chem 72, 146-159 DOI:10.1016/j.ejmech.2013.11.023, pdf + supplement mat Lucia Lintnerová, Melissa García-Caballero, Fridrich Gregáň, Milan Melicherčík, Ana R. Quesada, Juraj Dobiaš, Ján Lác, Marta Sališsová, Andrej Boháč A development of chimeric VEGFR2 TK inhibitor based on two ligand conformers from PDB: 1Y6A complex - Medicinal chemistry consequences of a TKs analysis

2013 Beilstein J Org Chem 9, 173-179 DOI:10.3762/bjoc.9.20, pdf, M. Murár, G. Addová, A. Boháč; Synthesis of 5-(ethylsulfonyl)-2-methoxyaniline: An important pharmacological fragment of VEGFR2 and other inhibitors.

2013 Central Eur J Chem 11 502-513 Renata Gašparová, Pavol Koiš, Margita Lácová, Silvia Kováčová, Andrej Boháč Synthesis, reactions and antineoplastic activity of 3-(2-oxo-2H-chromen-3-yl)-2-oxo-2H,5Hpyrano[3,2-c]chromene derivatives


M. Ilić, J. Ilaš, P. Dunkel, P. Mátyus, A. Boháč, S. Liekens, D. Kikelj, Novel 1,4-benzoxazine and 1,4-benzodioxine inhibitors of angiogenesis, 2012 Eur. J. Med. Chem. 58 160-170.

B. Gabajová, D. Valková, A. Boháč, E. Kováčová, R. Moravčík, M. Zeman; hVEGF165 Expression in Escherichia coli Conserves Its Biological Function 2012 J. of Chem. and Chem. Engineering 6 738-743.

M. Remko, A. Boháč, L. Kováčiková; Molecular structure, pKa, lipophilicity, solubility, absorption, polar surface area, and blood brain barrier penetration of some antiangiogenic agents, 2011 Structural Chem. 22 635-648.

S. Kováčová, L. Kováčiková, M. Lácová, A. Boháč, M. Sališová; Microwave assisted one pot synthesis of 7-substituted 2-(2-oxo-2H-chromen-3-yl)acetic acids as precursors of new anti-tumour compounds 2010 Chemical papers 64 806-811.

M. Lácová, R. Gašparová, P. Koiš, A. Boháč, H. M. El-Shaaer; A facile route to phenyl, phenylsulfanyl and phenylselanyl substituted pyrano[3,2-c]chromenes 2010 Tetrahedron 66 1410-1419.

L. Kováčiková, R. Gašparová, A. Boháč, M. Ďurana, M. Lácová; Synthesis of 3-phenyl-2H,5H-pyrano[3,2-c]chromen-2-one derivatives and their antineoplastic activit, 2010 ARKIVOC 11 188-203.

M. Pažický, V. Semak, B. Gášpár, A. Bílešová, M. Sališová, A. Boháč; Efficient synthesis of 2-alkyl-2-hydroxy-6-X-1-tetralones, 2008 ARKIVOC 8 225-241.

V. Semak, A. Boháč, M. Sališová, G. Addová, P. Danko; Preparation of alpha-methyl-gamma-butyrolactone: Mechanism of its formation and utilization in 2-methyl-1-tetralone synthesis, 2008 Chemical papers 62 275-280.

M. Lácová, H. Stankovičová, A. Boháč, B. Kotzianová, Convenient synthesis and unusual reactivity of 2-oxo-2H,5H-pyrano-[3,2-c]chromenes, 2008 Tetrahedron 64 9646-9653.

A. Almássy, Z. Benková, B. Horváth, A. Boháč; Fluxional behavior of methyl-substituted tricarbonyl(tropone)iron complexes and their different reactivity, 2008 J. of Organometal. Chem. 693 3223-3232.

M. Pažický, B. Gášpár, A. Solladié-Cavallo, M. Sališová, A. Boháč, M. Hutta, G. Addová; The epimerization of chiral alpha-amino acids by 2-hydroxy-2-methyl-1-tetralone template - The synthesis, conditions and mechanism of isomerization, 2006 Synthesis – Stuttgart 12 2013-2018.

V. Langer, D. Gyepesová, P. Mach, E. Scholtzová, B. Gášpár, M. Sališová, A. Boháč; Anti-2-Hydroxy-2-methyl-1-tetralone oxime: X-ray and density functional theory study, 2006 Acta Crystallographica Section C-Crystal Structure Communications 62 o199-o202,
URL: http://www.blackwell-synergy.com/doi/full/10.1107/S0108270106005178.

O. Šedý, A. Solladié-Cavallo, M. Sališová, A. Boháč; Organické fosfazénové bázy a ich využitie v organickej chémii 2004 Chemické listy 98 964-969.

L. Soják, G. Addová, R. Kubinec, A. Kraus, A. Boháč; Capillary gas chromatography-mass spectrometry of all 93 acyclic octenes and their identification in fluid catalytic cracked gasoline, 2004 J. of Chromatography A 1025 237-253.

A. Almássy, B. Horváth, A. Boháč, M. Sališová, G. Addová, M. Rosenblum; Thermodynamic and kinetic parameters associated with the fluxional behavior of 2-methyl- and 2,6-dimethyltroponeiron tricarbonylcomplexes 2004 J. of Organometal. Chem. 689 1131-1138.

B. Horváth, A. Boháč, M. Sališová, E. Solčániová, M. Rosenblum; The synthesis of a hydroazulen-2-one skeleton-determination of the diastereoselectivity of [3+2] cycloaddition oftricarbonyl[4,5,6,7-n)-2-methyltropone]iron with E/Z-hapto1-(crotyl)Fp, 2002 J. of Organometal. Chem. 659 43-49.

A. Almássy, M. Pažický, A. Boháč, M. Sališová, G. Addová, M. Rosenblum; Synthesis of 2,6-Dimethyltropone - A New, Convenient Methodology from 2,6-Dimethylcyclohexanone 2002 Synthesis – Stuttgart 12 1695-1700.

G. Addová, L. Soják, R. Kubinec, A. Boháč; The comparison of GC behaviour of acyclic C5-C8 alkenes on squalane and silicone OV-1 stationary phases, 2000 Chemické listy 94 962-963.

R. Kubinec, L. Soják, R. Górová, G. Addová, A. Boháč; The separation of stereoisomers using recycle capillary gas chromatography, 1999 Enantiomer 4 345-350.

A. Boháč, M. Lettrichová, P. Hrnčiar, M. Hutta, Milan; Cyclic beta-diketones - precursors of chiral 1,3-cyclohexadiene iron carbonyl complexes. Ligard exchange - (-)-PPh2(O-HC(Me)-COOEt) - new, chiral, diastereomer-separating ligand in organoiron chemistry, 1996 J. of Organometal. Chem. 507 23-29.

A. Boháč; A transferable gas container (TGC) - improving the balloon inert atmosphere technique, 1995 J. of Chem. Education 72 1995 263-263.

Y. N. Ito, X. Ariza, A. K. Beck, A. Boháč, C. Ganter, R. E. Gawley, F. N. M. Kuhnle, J. Tuleja, Y. M. Wang, D. Seebach; Preparation and structural analysis of several newalpha,alpha,alpha,alpha-tetraaryl-1,3-dioxolane-4,5-dimethanols (TADDOL's) and TADDOL analogs, their evaluation as titanium liganst in the enantioselective addition of methyltitanium and diethylzinc reagents to benzaldehyde, and refinement of the mechanistic hypothesis, 1994 Helvetica Chimica Acta 77 2071-2110.

G. J. Matare, A. Boháč, P. Hrnčiar; Acetylation of beta-Diketone Copper(II) Chelates by Treatment with Ketene 1994 Synthesis – Stuttgart 4 381-382.

A. Boháč, P. Hrnčiar, J. Šraga; Acetylation of 2-acyl-1,3-indandiones with ketene and Determination of the Structure of Products 1992 Chemical papers 46 31-34.

A. Boháč, P. Hrnčiar; 3-Acetoxy-2-cykloalken-1-one by acetylation of cyclic 1,3-diketones with ketene; 1991 Collection of Czechoslovak Chem. Commun. 56 2879-2883.

A. Boháč, P. Hrnčiar; A Convenient Synthesis of 1,3-Diacetoxy-1,3-cycloalkadienes from Cyclic beta-diketones, 1991 Synthesis - Stuttgart. 10 881-882.

A. Boháč, A. Perjéssy, D. Loos, P. Hrnčiar; Elucidation of Acetylation Products of 2-Acyl-1,3-indanediones by Correlation of Infrared Spectral Data, 1991 Monatshefte für Chemie 122 943-948.